Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Effectiveness of heterologous COVID-19 vaccine booster dosing in Brazilian healthcare workers, 2021.

Effectiveness of heterologous COVID-19 vaccine booster dosing in Brazilian healthcare workers, 2021. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Marra, A. R., Miraglia, J. L., Malheiros, D. T., Guozhang, Y., Teich, V. D., da Silva Victor, E., Pinho, J. R., Cypriano, A., Vieira, L. W., Polonio, M., Ornelas, R. H., de Oliveira, S. M., Borges Junior, F. A., Oler, S. C., de Paula Pinto Schettino, G., de Oliveira, K. G., Santana, R. A., de Mello Malta, F., Amgarten, D., Boechat, A. L., Trecenti, N. M., Kobayashi, T., Salinas, J. L., Edmond, M. B., Rizzo, L. V. 2022

Abstract

Little is currently known about vaccine effectiveness (VE) for either two doses of Oxford-AstraZeneca (ChAdOx1) viral vector vaccine or CoronaVac inactivated viral vaccine followed by a third dose of mRNA vaccine (Pfizer/BioNTech) among healthcare workers (HCWs).We conducted a retrospective cohort study among HCWs (aged =18 years) working in a private healthcare system in Brazil from January to December 2021. VE was defined as 1-IRR (incidence rate ratio), with IRR determined using Poisson models with the occurrence of laboratory-confirmed COVID-19 infection as the outcome, adjusting for age, sex, and job type. We compared those receiving viral vector or inactivated viral primary series (two doses) to those who received an mRNA booster.A total of 11,427 HCWs met the inclusion criteria. COVID-19 was confirmed in 31.5% of HCWs receiving two doses of CoronaVac vaccine vs. 0.9% of HCWs receiving two doses of CoronaVac vaccine with mRNA booster (p?

View details for DOI 10.1093/cid/ciac430

View details for PubMedID 35639918